Developer docs
API playgroundTry for free, no card

Search company profiles

Novadiscovery

Full company profile

uuid0002fh3

Namestring
Novadiscovery
Legal namestring
Nova
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Nova In Silico (also branded Novadiscovery) is a French health technology company founded in 2010 and headquartered in Lyon, France, that develops the jinkō clinical trial simulation platform for the pharmaceutical industry. The platform combines data science, biology, and medicine to predict clinical trial outcomes before studies are conducted in human subjects, using computational disease models and virtual patient populations to simulate treatment efficacy, optimize protocol design, and identify responder subgroups. Specific disease models have been developed across therapeutic areas including asthma, hypoparathyroidism, and hepatitis B (HBV), with documented applications spanning drug discovery, clinical development, and market access phases.

The jinkō platform is positioned as the first collaborative clinical trial simulation platform and offers a model library, virtual patient generation, simple protocol design tools, and collaborative curation capabilities. It is complemented by a Digital Twin for Clinical R&D offering that generates virtual populations and simulates disease progression and treatment responses. The company markets the platform as reducing clinical trial duration, minimizing human subject risk, and producing payer-grade evidence packages within months rather than years.

Nova In Silico serves pharmaceutical companies through an enterprise field sales motion with a demo-based acquisition approach. The company generates revenue through SaaS-style subscriptions and project-based engagements with global pharma clients including Takeda (applied to Natpar for hypoparathyroidism) and ENYO Pharma (applied to Vonafexor for HBV across 700+ trial designs). The company also engages in industry positioning through white papers, webinars, and conference participation, and in June 2025 announced a strategic collaboration with Fujitsu to integrate AI-powered simulation capabilities into the platform.

Short descriptiontext

Nova In Silico (Novadiscovery) is a French health technology company that provides the jinkō clinical trial simulation platform, using disease models and digital patient populations to predict drug efficacy and optimize trial design for pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial simulation, in silico trials, digital twin technology, pharmaceutical R&D software, virtual patient modeling
Industry4 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAGACAB
Site Identification & Feasibility
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code4 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
  • Computer Systems Design Services541512
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Prepackaged Software7372
Product category
Pharmaceutical R&D Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1jinkō Platform Subscription
TypeSubscription Recurring
Description

SaaS-based simulation platform likely offered through subscription model given the enterprise sales motion and demo-based acquisition approach. The platform is described as 'the first collaborative clinical trial simulation platform' suggesting a software-as-a-service delivery model.

novainsilico.ai
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1jinkō
Description

The first collaborative clinical trial simulation platform that streamlines clinical trials using disease models and digital patients, predicting clinical outcomes before trials in human subjects.

novainsilico.ai
Core offering1 text field

Novadiscovery develops and sells jinkō, a collaborative clinical trial simulation platform that uses disease models and digital patients to predict clinical trial outcomes before human testing. The platform enables pharmaceutical companies to design, simulate, and analyze virtual trials across hundreds of protocol variations, supporting applications from target identification through clinical development and market access evidence generation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Reduce clinical trial duration and number of experiments
+3 more records
Product overview1 text field

Nova In Silico (Novadiscovery) operates as a clinical trial simulation company offering jinkō, a cloud-based collaborative simulation platform. The platform is complemented by Digital Twin capabilities for clinical R&D and a library of disease-specific models for virtual patient simulation. The product architecture spans applications from drug discovery through market access, enabling pharmaceutical companies to reduce trial duration, minimize human subject risk, and optimize treatment protocol design through in silico methodologies.

Product and service1 record
1jinkō Simulation Platform
CategoryClinical Trial Simulation Software
Description

A collaborative clinical trial simulation SaaS platform that combines data science, biology, and medicine to predict clinical outcomes before trials in human subjects. Features include a model library with virtual patients, simple protocol design, knowledge management and collaborative curation, and an intuitive analysis interface for clinical trial experts. Sold to large pharmaceutical companies for protocol optimization, responder identification, and payer evidence generation.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Fujitsu
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-24
Description

Nova In Silico announced collaboration with Fujitsu on June 24, 2025 to transform clinical trials through advanced AI-powered simulations. This partnership aims to leverage Fujitsu's technology capabilities with NovaDiscovery's jinkō simulation platform to enhance clinical trial design and execution using artificial intelligence.

novainsilico.ai
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novadiscovery

Pharmaceutical R&D Softwarenovadiscovery.com

Nova In Silico (Novadiscovery) is a French health technology company that provides the jinkō clinical trial simulation platform, using disease models and digital patient populations to predict drug efficacy and optimize trial design for pharmaceutical companies.

What Novadiscovery does

Nova In Silico (also branded Novadiscovery) is a French health technology company founded in 2010 and headquartered in Lyon, France, that develops the jinkō clinical trial simulation platform for the pharmaceutical industry. The platform combines data science, biology, and medicine to predict clinical trial outcomes before studies are conducted in human subjects, using computational disease models and virtual patient populations to simulate treatment efficacy, optimize protocol design, and identify responder subgroups. Specific disease models have been developed across therapeutic areas including asthma, hypoparathyroidism, and hepatitis B (HBV), with documented applications spanning drug discovery, clinical development, and market access phases.

The jinkō platform is positioned as the first collaborative clinical trial simulation platform and offers a model library, virtual patient generation, simple protocol design tools, and collaborative curation capabilities. It is complemented by a Digital Twin for Clinical R&D offering that generates virtual populations and simulates disease progression and treatment responses. The company markets the platform as reducing clinical trial duration, minimizing human subject risk, and producing payer-grade evidence packages within months rather than years.

Nova In Silico serves pharmaceutical companies through an enterprise field sales motion with a demo-based acquisition approach. The company generates revenue through SaaS-style subscriptions and project-based engagements with global pharma clients including Takeda (applied to Natpar for hypoparathyroidism) and ENYO Pharma (applied to Vonafexor for HBV across 700+ trial designs). The company also engages in industry positioning through white papers, webinars, and conference participation, and in June 2025 announced a strategic collaboration with Fujitsu to integrate AI-powered simulation capabilities into the platform.

Novadiscovery firmographics

Firmographics
Name
Novadiscovery
Legal name
Nova
Website
https://novadiscovery.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Nova In Silico (Novadiscovery) is a French health technology company that provides the jinkō clinical trial simulation platform, using disease models and digital patient populations to predict drug efficacy and optimize trial design for pharmaceutical companies.
Ownership category
akta.pro rank

Novadiscovery industry classification

Industry
Product category
Pharmaceutical R&D Software
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAGACAB
Site Identification & Feasibility
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Clinical trial simulation
  • In silico trials
  • Digital twin technology
  • Pharmaceutical R&D software
  • Virtual patient modeling

Where Novadiscovery is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Novadiscovery business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. jinkō Platform Subscription: SaaS-based simulation platform likely offered through subscription model given the enterprise sales motion and demo-based acquisition approach. The platform is described as 'the first collaborative clinical trial simulation platform' suggesting a software-as-a-service delivery model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Novadiscovery product offering

Product offering

Core offering

Novadiscovery develops and sells jinkō, a collaborative clinical trial simulation platform that uses disease models and digital patients to predict clinical trial outcomes before human testing. The platform enables pharmaceutical companies to design, simulate, and analyze virtual trials across hundreds of protocol variations, supporting applications from target identification through clinical development and market access evidence generation.

Product overview

Nova In Silico (Novadiscovery) operates as a clinical trial simulation company offering jinkō, a cloud-based collaborative simulation platform. The platform is complemented by Digital Twin capabilities for clinical R&D and a library of disease-specific models for virtual patient simulation. The product architecture spans applications from drug discovery through market access, enabling pharmaceutical companies to reduce trial duration, minimize human subject risk, and optimize treatment protocol design through in silico methodologies.

Differentiator

Problem solved

Functional benefit

Brands

  • jinkō: The first collaborative clinical trial simulation platform that streamlines clinical trials using disease models and digital patients, predicting clinical outcomes before trials in human subjects.

Products and services

  • jinkō Simulation Platform A collaborative clinical trial simulation SaaS platform that combines data science, biology, and medicine to predict clinical outcomes before trials in human subjects. Features include a model library with virtual patients, simple protocol design, knowledge management and collaborative curation, and an intuitive analysis interface for clinical trial experts. Sold to large pharmaceutical companies for protocol optimization, responder identification, and payer evidence generation.

Quantifiable outcome

  • Reduce clinical trial duration and number of experiments
  • +3 more outcomes

Companies that use Novadiscovery

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Novadiscovery technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Novadiscovery partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • FujitsucoreTechnology or Integration · 24 June 2025Nova In Silico announced collaboration with Fujitsu on June 24, 2025 to transform clinical trials through advanced AI-powered simulations. This partnership aims to leverage Fujitsu's technology capabilities with NovaDiscovery's jinkō simulation platform to enhance clinical trial design and execution using artificial intelligence.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Novadiscovery competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Novadiscovery social profiles

Digital presence

Novadiscovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novadiscovery leadership team

Management profile

Number of profiles

Novadiscovery funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novadiscovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novadiscovery

What does Novadiscovery do?

Novadiscovery develops and sells jinkō, a collaborative clinical trial simulation platform that uses disease models and digital patients to predict clinical trial outcomes before human testing. The platform enables pharmaceutical companies to design, simulate, and analyze virtual trials across hundreds of protocol variations, supporting applications from target identification through clinical development and market access evidence generation.

Is Novadiscovery a public or private company?

Novadiscovery is a private company. It is classified as venture growth investor backed and is currently operating.

When was Novadiscovery founded?

Novadiscovery was founded in 2010. It employs 11 to 50 people.

Where is Novadiscovery based?

Novadiscovery is headquartered in Lyon, France, in the Europe region.

How does Novadiscovery make money?

One revenue line is on record: jinkō Platform Subscription.

Does Novadiscovery have an API?

No public API is recorded for Novadiscovery.

What industry is Novadiscovery in?

Novadiscovery's product category is Pharmaceutical R&D Software. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewslineBritish explorer secures domestic partners for major copper development in KazakhstanEast Star Resources signed an agreement with Nova Ltd to form a joint venture for the Rulikha copper project in Kazakhstan's East Kazakhstan region. Orion Development Ltd will act as project operator, and East Star registered Rulikha Ltd in the Astana International Financial Centre.GlobeNewswireNew demonstration of the predictive power of an in silico clinical trial in oncologyNovadiscovery's jinkō platform predicted the MARIPOSA Phase III trial results, sharing them a week before the ESMO 2023 conference. The simulation predicted an HR of 0.60 and median time to progression of 26.3 months for the combination arm. The actual trial showed a 30% reduction in progression risk with the combination treatment.GlobeNewswireNovadiscovery announces Nature Communications paper on modeling the disruption to respiratory clinical trials due to mitigation measures against COVID-19Novadiscovery published a Nature Communications paper with OM Pharma on a model of respiratory tract infections to assess how COVID-19 mitigation measures disrupted respiratory clinical trials. The model used virtual populations and in silico trials to show impacts and suggest adaptations like recruitment numbers and adaptive designs. The authors recommend reporting varying benefit metrics and reassessing eligibility criteria.GlobeNewswireNovadiscovery expands Janssen collaboration by implementing its JINKO® clinical trial simulation platform for the development of lung cancer modelsNovadiscovery expanded its collaboration with Janssen by applying its JINKO clinical trial simulation platform to develop lung cancer models. The platform will add biological complexity to the initial disease model and run in silico trial simulations. The companies aim to streamline clinical development and accelerate patient access to treatments.GlobeNewswireNovadiscovery Continues Global Expansion with the Launch of its US Headquarters in Boston, MANovadiscovery opened its US headquarters in Boston, Massachusetts, as part of its international expansion. The new office supports access to its Jinkō platform and includes relocated SVP Sales and Marketing Charlotte Turnier. The company aims to accelerate adoption of its in silico clinical trial simulation platform in the US market.GlobeNewswireNovadiscovery appoints Grégoire Boutonnet as Chief Operating OfficerNovadiscovery appointed Grégoire Boutonnet as Chief Operating Officer, effective immediately. He brings over 20 years of experience, including roles at Andrexen, Cirpack, and Experty.io. The appointment supports NOVA's international expansion and its Jinkō platform.GlobeNewswireNovadiscovery announces new clinical simulation collaboration with TakedaNovadiscovery announced a new collaboration with Takeda to incorporate its clinical simulation platform JINKO into Takeda France's access strategy. The agreement builds on a 2017 relationship and aims to use virtual patient simulation to support health technology assessment for Takeda's innovative therapies.GlobeNewswireNovadiscovery raises Series A2 financing from Sanofi to advance JINKO, its best-in-class clinical trial simulation platformNovadiscovery raised €2.5 million in a Series A2 financing round from Sanofi. The funds will advance its JINKO clinical trial simulation platform, support US expansion, and develop a COVID-19 disease model. Sanofi's Global Head of Digital Innovation will join the board.YahooConsortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host diseaseBpifrance awarded €3.35 million to a consortium including ElsaLys Biotech and Novadiscovery to advance inolimomab for graft-versus-host disease. The funding supports in silico trials via NOVA's Jinkō platform and academic research on the drug's mechanisms. ElsaLys has already submitted a US BLA and received a French temporary authorization.GlobeNewswireConsortium including ElsaLys Biotech and Novadiscovery awarded €3.35 million by Bpifrance to advance inolimomab in graft-versus-host diseaseBpifrance awarded €3.35 million to a consortium including ElsaLys Biotech and Novadiscovery to advance inolimomab for graft-versus-host disease. The funding supports in silico trials via NOVA's Jinkō platform and academic research on the drug's mechanisms. The consortium aims to accelerate European approval for the drug.